1. Home
  2. IMRN

as 04-01-2025 3:37pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Founded: 1994 Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 10.1M IPO Year: N/A
Target Price: $5.00 AVG Volume (30 days): 13.6K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.02 EPS Growth: N/A
52 Week Low/High: $1.70 - $3.09 Next Earning Date: 04-08-2025
Revenue: $4,048,286 Revenue Growth: 82.90%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

IMRN Daily Stock ML Predictions

Share on Social Networks: